Primary endocrine therapy versus surgery plus endocrine therapy for early-stage breast cancer in older women without frailty: a cost-effectiveness and value of implementation analysis.

ABSTRACT:

Background

Clinical guidelines recommend surgery for early-stage breast cancer in operable patients; however, primary endocrine therapy (PET) is often used in older women aged ≥ 70. This study aimed to estimate the cost-effectiveness and value of implementation of surgery plus adjuvant endocrine therapy (ET) compared with PET for older women with early breast cancer who are fit for surgery.

Method

A partitioned survival analysis model was developed using effectiveness data from the published literature (time horizon: lifetime). Health outcomes were measured as quality-adjusted life years (QALYs; EQ-5D-3L UK tariff). Direct costs were estimated from the perspective of NHS England (discount rate: 3.5%). Probabilistic sensitivity analysis and value of implementation analysis we

SUBMITTER: Wang Y 

PROVIDER: S-EPMC12487327 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature